Summary sheet
The project concerns investments in research and development (R&D) activities and in the construction of an advanced manufacturing plant that will be located in existing promoter facilities in Belgium.
The project aims at improving the health of European citizens, increasing the competitiveness and boosting the innovative capacity of European health-related industries and businesses. The project focuses on neuroscience and immunology in particular neuro-degeneration, neuro-inflammation and rare diseases as well as autoimmune diseases, which are mostly still underserved and leave a high clinical unmet need.
The project includes the construction of a new plant to manufacture pharmaceutical products. This activity is listed in the Annex II of the Environmental Impact Assessment (EIA) Directive. Whether a EIA under the directive 2014/52/EU is required and other environmental details will be verified during the project appraisal.
The Promoter is a private company not operating in the Utilities sector and not having a status of a contracting entity. Thus it is not covered by EU Directives on procurement.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).
Documents
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Media enquiries
Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.
Complaints mechanism
Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
Related publications